Published Technical Disclosure Archive

Enhanced Compositions and Methods for Treating Spinal Muscular Atrophy

Publication ID: 24-11857599_0006_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Compositions and Methods for Treating Spinal Muscular Atrophy,” Published Technical Disclosure No. 24-11857599_0006_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857599_0006_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,599.

Summary of the Inventive Concept

The present inventive concept relates to novel compositions and methods for treating spinal muscular atrophy (SMA) by improving the efficacy and delivery of recombinant ALK4:ActRIIB heteromultimers, thereby enhancing treatment outcomes and patient quality of life.

Background and Problem Solved

The original patent disclosed compositions and methods for treating SMA using recombinant ALK4:ActRIIB heteromultimers. However, the patent's limitations included potential issues with ligand binding affinity, delivery to motor neurons, and bioavailability. The present inventive concept addresses these limitations by introducing modified heteromultimers with increased ligand binding affinity, conjugation to targeting moieties, controlled release devices, and formulations with permeation enhancers.

Detailed Description of the Inventive Concept

The new inventive concept comprises four main aspects. Firstly, the recombinant ALK4:ActRIIB heteromultimer is modified to have increased ligand binding affinity, thereby improving treatment efficacy. Secondly, the heteromultimer is conjugated to a targeting moiety to enhance delivery to motor neurons. Thirdly, a system is designed for controlled release of the heteromultimer over a prolonged period of time. Finally, the heteromultimer is formulated with a permeation enhancer to improve bioavailability. These improvements enable more effective treatment of SMA, leading to better patient outcomes.

Novelty and Inventive Step

The novelty of the present inventive concept lies in the combination of these four aspects, which provide a significant improvement over the original patent. The inventive step resides in the recognition of the limitations of the original patent and the development of innovative solutions to address these limitations, resulting in a more effective and efficient treatment for SMA.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include the use of different targeting moieties, controlled release devices, and permeation enhancers. Additionally, the heteromultimer could be formulated with other therapeutic agents to provide a combination therapy for SMA.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of SMA. The improved efficacy and delivery of the recombinant ALK4:ActRIIB heteromultimer could lead to increased adoption and market share in the SMA treatment market.

CPC Classifications

SectionClassGroup
A A61 A61K38/1841
A A61 A61K31/7125
A A61 A61K38/18
A A61 A61K45/06
A A61 A61P21/00
C C07 C07K14/71
C C12 C12N15/113
A A61 A61K38/179
C C07 C07K2319/30
C C07 C07K2319/32
C C12 C12N2310/11
C C12 C12N2320/31

Field of Art

Biotechnology and pharmaceutical sciences, specifically neuromuscular disorder therapeutics, with expertise in protein engineering, recombinant protein design, and targeted drug delivery for genetic disorders

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or bioengineering, familiar with protein modification techniques, drug delivery strategies, and therapeutic approaches for rare genetic disorders like spinal muscular atrophy

Obviousness Rationale

A person skilled in the art would recognize that the proposed modifications to the ALK4:ActRIIB heteromultimer represent predictable engineering improvements that address known limitations in the original treatment approach. The variations demonstrate standard optimization strategies commonly employed in protein therapeutic development, including enhanced binding affinity, targeted delivery, controlled release, and improved bioavailability. These modifications would be considered routine design choices for a skilled practitioner seeking to improve the efficacy of an existing therapeutic approach.

Obvious Combinations & Variations

Source Patent Element
Recombinant ALK4:ActRIIB heteromultimer for treating spinal muscular atrophy
PTD Variation
Modifying the heteromultimer to increase ligand binding affinity
Obviousness Reasoning
Protein engineering techniques for improving binding affinity are well-established and represent a predictable optimization strategy in therapeutic protein design
Source Patent Element
Method of treating SMA by administering heteromultimer
PTD Variation
Conjugating the heteromultimer to a targeting moiety for enhanced motor neuron delivery
Obviousness Reasoning
Targeted drug delivery is a known approach in therapeutic development, with numerous established techniques for improving cellular specificity and treatment efficacy
Source Patent Element
Administration of heteromultimer for SMA treatment
PTD Variation
Implementing controlled release mechanisms for sustained drug delivery
Obviousness Reasoning
Controlled release technologies are standard pharmaceutical engineering techniques for improving drug pharmacokinetics and patient treatment outcomes
Source Patent Element
Pharmaceutical composition for SMA treatment
PTD Variation
Formulating the heteromultimer with permeation enhancers to improve bioavailability
Obviousness Reasoning
Permeation enhancement is a well-known strategy in drug formulation to address absorption and distribution challenges in therapeutic compounds
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857599 and the disclosed technical variations, a person having ordinary skill in the art would find the proposed modifications to the ALK4:ActRIIB heteromultimer treatment approach obvious and predictable. The incremental improvements in protein engineering, targeted delivery, and formulation represent standard optimization strategies that would be readily apparent to a skilled practitioner in the field of neuromuscular disorder therapeutics.

Original Patent Information

Patent NumberUS 11,857,599
TitleCompositions and methods for treating spinal muscular atrophy
Assignee(s)ACCELERON PHARMA INC.